Corresponding author: Vasyl Matiychuk ( v_matiychuk@ukr.net ) Academic editor: Georgi Momekov
© 2021 Volodymyr Horishny, Taras Chaban, Vasyl Matiychuk.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Horishny V, Chaban T, Matiychuk V (2021) Synthesis and anticancer properties of 5-(1 H-benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-ylcarboxilic acids. Pharmacia 68(1): 195-200. https://doi.org/10.3897/pharmacia.68.e49224
|
The reaction of 1H-benzoimidazole-2-carbaldehyde with 4-oxo-2-thioxothiazolidin-3-ylcarboxilic acids was studied and the combinatorial library of 5-(1H-benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-ylcarboxilic acids has been prepared. The structures of target compounds 8a-f, 9 and 10a, b were confirmed by using 1H NMR spectroscopy and elemental analysis. The synthesized compounds were selected by the National Cancer Institute (NCI) Developmental Therapeutic Program for the in vitro cell line screening to investigate their anticancer activity. The tested compounds displayed a weak to medium anticancer activity. The most sensitive cell lines turned out to be SNB-75 of CNS Cancer (GP = 74.84–85.73%) and UO-31, Renal cancer (GP = 71.53–82.16%) and to compound 10a K-562 Leukemia cell lines (GP = 57.14).
Graphical abstract
organic synthesis, 5-(1H-benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-ylcarboxilic acids, anticancer properties
Benzimidazoles and its derivatives are an important group of heterocyclic compounds that show a wide range of pharmacological properties such as antitumor, antimicrobial, antihypertensive, antiviral, antiulcer, anticonvulsant, antiinflammatory activities. Their widespread use as scaffolds in medicinal chemistry establishes this moiety as a member of the class of privileged structures (
On the other hand a detailed study of rhodanine (2-thioxo-4-thiazolidone) derivatives has made it possible to identify a lot of highly active agents with a wide range of biological activity. Among the 5-arylidenerhodanines, a lot of lead- compounds that possess various activities, including antimicrobial, antituberculous, antiviral, antidiabetic, anti-inflammatory, antitumor, anticonvulsant activities have been also found. At the present stage of development of medical chemistry, the rhodanine motif is considered to be also privileged (
These diverse biological applications of benzimidazole and rhodanine compounds have motivated new efforts in search for novel their hybrids derivatives with improved biological activity and diverse applications in pharmaceutical industry.
All chemicals were of analytical grade and commercially available. All reagents and solvents were used without further purification and drying. All the melting points were determined in an open capillary and are uncorrected.1H- spectra were recorded on a Varian Mercury 400 (400 MHz for 1H) instrument with TMS or deuterated solvent as an internal reference. Satisfactory elemental analyses were determined on a Elementar Vario L cube instrument (C±0.17, H±0.21, N±0.19).
2-Dichloromethyl-1H-benzoimidazole hydrochloride (3) . 0.2 Mol benzene-1,2-diamine, 0.26 mol dichloroacetic acid in 180 ml 20% hydrochloric acid were refluxed for 20 hours. Cooled to 0 °C, the precipitated of -dichloromethyl-1H-benzoimidazole hydrochloride was filtered off and washed with cold 20% hydrochloric acid and water. Yield 35g (74%). The obtained dichloromethyl-1H-benzoimidazole hydrochloride was used without further purification.
1H-Benzoimidazole-2-carbaldehyde (4) . 0,14 Mol of dichloromethyl-1H-benzoimidazole hydrochloride та 0,7 mole sodium acetate water 300 ml water stirred for 2 hours at 90–95 ºС. Cooled to room temperature. The precipitated of 1H-benzoimidazole-2-carbaldehyde was filtered off and washed with water, methanol and diethyl ether, dried and recrystallize from DMF. Yield 18,1г (89%), m. p. 235°С.
General procedure of the synthesis 5-(1H-benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-ylcarboxilic acids 8-10. The solution of 3 mmol 4-oxo-2-thioxothiazolidin-3-ylcarboxilic acids, 3.6 mmol 1H-benzoimidazole-2-carbaldehyde and 3 mmol anhydrous sodium acetate in 7 ml acetic acid was refluxed for 1 hours. Cooled to room temperature. The precipitated was filtered off and washed with acetic acids and water, dried and recrystallize from acetic acid or acetic acid-DMF.
[5-(1H-Benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]acetic acid (8a). Yield 77%; m.p. = 272 °C decomp. 1H NMR (400 MHz, DMSO-d6) d 13.49 (s, 1H, COOH), 13.16 (s, 1H, NH), 7.80 (d, J = 7.8 Hz, 1H, benzoimidazole), 7.68 (s, 1H, CH=), 7.65 (d, J = 7.7 Hz, 1H, benzoimidazole), 7.33 (dt, J = 15.3, 6.7 Hz, 2H, benzoimidazole), 4.70 (s, 2H, CH2). Anal. Calculated for C13H9N3O3S2 %: C, 48.89; H, 2.84; N, 13.16. Found %: C, 48.70; H, 2.78; N, 13.21.
2-[5-(1H-Benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]-3-methylbutyric acid (8b). Yield 94%; m.p. = 260 °C decomp. 1H NMR (400 MHz, d DMSO-d6) d 13.26 (s, 1H, COOH), 13.20 (s, 1H, NH), 7.80 (d, J = 7.8 Hz, 1H, benzoimidazole), 7.67 (s, 1H, CH=), 7.65 (d, J = 7.6 Hz, 1H, benzoimidazole), 7.38–7.27 (m, 2H, benzoimidazole), 5.19 (d, J = 8.6 Hz, 1H, CH), 2.72 (dt, J = 20.8, 10.4 Hz, 1H, CH), 1.20 (d, J = 6.5 Hz, 3H, CH3), 0.76 (d, J = 6.9 Hz, 3H, CH3). Anal. Calculated for C16H15N3O3S2 %: C, 53.17; H, 4.18; N, 11.63. Found %: C, 53.18; H, 4.25; N, 11.55.
2-[5-(1H-Benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]-4-methylpentanoic acid (8c). Yield 99%; m.p. = 244 °C decomp. 1H NMR (400 MHz, DMSO-d6) d 13.36 (s, 1H, COOH), 13.18 (s, 1H, NH), 7.80 (d, J = 7.4 Hz, 1H, benzoimidazole), 7.64 (s, 2H benzoimidazole + CH=), 7.38–7.27 (m, 2H, benzoimidazole), 5.59 (s, 1H, CH), 2.18 (d, J = 9.6 Hz, 1H, CH), 2.02 (ddd, J = 13.0, 8.5, 4.3 Hz, 1H, CH), 1.50 (s, 1H, CH), 0.92 (d, J = 6.5 Hz, 3H, CH3), 0.87 (d, J = 6.6 Hz, 3H, CH3). Anal. Calculated for C17H17N3O3S2 %: C, 54.38; H, 4.56; N, 11.19. Found %: C, 54.66; H, 4.62; N, 11.29.
2-[5-(1H-Benzoimidazol-2-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-3-methylpentanoic acid (8d). Yield 66%; m.p. = 259 °C decomp. 1H NMR (400 MHz DMSO-d6) d 13.25 (s, 1H, COOH), 13.20 (s, 1H, NH), 7.80 (d, J = 7.9 Hz, 1H, benzoimidazole), 7.66 (s, 1H, benzoimidazole), 7.64 (s, 1H, CH=), 7.33 (dt, J = 15.0, 6.9 Hz, 2H. benzoimidazole), 5.24 (d, J = 9.0 Hz, 1H, CH), 1.25 (s, 1H, CH), 1.16 (d, J = 6.4 Hz, 3H, CH3), 0.96 (s, 1H, CH), 0.80 (t, J = 7.3 Hz, 3H, CH3). Anal. Calculated for C17H17N3O3S2 %: C, 54.38; H, 4.56; N, 11.19. Found %: C, 54.57; H, 4.44; N, 11.33.
2-[5-(1H-Benzoimidazol-2-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-3-phenylpropionic acid (8e). Yield 83%; m.p. = 258 °C decomp. 1H NMR (400 MHz, DMSO-d6) d 13.49 (s, 1H, COOH), 13.15 (s, 1H, NH), 7.76 (d, J = 7.9 Hz, 1H, benzoimidazole), 7.64 (d, J = 7.9 Hz, 1H, benzoimidazole), 7.60 (s, 1H, CH=), 7.32 (dt, J = 15.2, 6.8 Hz, 2H, benzoimidazole), 7.24–7.12 (m, 5H, Ph), 5.88 (s, 1H, CH), 3.51 (d, J = 5.6 Hz, 2H, CH2). Anal. Calculated for C20H15N3O3S2 %: C, 58.66; H, 3.69; N, 10.26. Found %: C, 58.74; H, 3.55; N, 10.25.
2-[5-(1H-Benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]-3-(4-hydroxy-phenyl)propionic acid (8f). Yield 99%; m.p. = 278 °C decomp. 1H NMR (400 MHz, DMSO-d6) d 13.18 (s, 1H, NH), 9.20 (s, 1H, OH), 7.77 (d, J = 7.9 Hz, 1H, benzoimidazole), 7.64 (d, J = 7.7 Hz, 1H, benzoimidazole), 7.60 (s, 1H, CH=), 7.32 (dt, J = 15.2, 7.0 Hz, 2H, benzoimidazole), 6.93 (d, J = 8.3 Hz, 2H, C6H4OH), 6.57 (d, J = 8.4 Hz, 2H, C6H4OH), 5.78 (s, 1H, CH), 3.36 (s, 2H, CH2). Anal. Calculated for C20H15N3O3S2 %: C, 56.46; H, 3.55; N, 9.88. Found %: C, 56.14; H, 3.41; N, 9.61.
3-[5-(1H-Benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]propionic acid (9). Yield 95%; m.p. = 262 °C decomp. 1H NMR (400 MHz, DMSO-d6) d 13.08 (s, 1H, NH), 12.44 (s, 1H, COOH), 7.78 (d, J = 7.8 Hz, 1H, benzoimidazole), 7.64 (s, 1H, CH=), 7.61 (s, 1H, benzoimidazole), 7.37–7.26 (m, 2H, benzoimidazole), 4.24 (t, J = 7.7 Hz, 2H, CH2), 2.65 (t, J = 7.7 Hz, 2H, CH2). Anal. Calculated for C14H11N3O3S2 %: C, 50.44; H, 3.33; N, 12.60. Found %: C, 50.16; H, 3.29; N, 12.48.
3-[5-(1H-Benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]benzoic acid (10a). Yield 77%; m.p. = >280 °C. 1H NMR (400 MHz, DMSO-d6) d 13.12 (s, 1H, NH), 8.08 (dd, J = 5.8, 2.7 Hz, 1H, Ar), 8.04 (s, 1H, Ar), 7.83 (d, J = 7.6 Hz, 1H, benzoimidazole), 7.73–7.69 (m, 2H, Ar), 7.67 (d, J = 6.4 Hz, 1H, benzoimidazole), 7.65 (s, 1H, CH=), 7.38–7.28 (m, 2H, benzoimidazole). Anal. Calculated for C18H11N3O3S2 %: C, 56.68; H, 2.91; N, 11.02. Found %: C, 56.44; H, 3.12; N, 11.25.
5-[5-(1H-Benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]-2-hydroxybenzoic acid (10b). Yield 90%; m.p. = 279 °C decomp. 1H NMR (400 MHz, DMSO-d6) d 13.10 (s, 1H), 7.88 (s, 1H, benzoimidazole), 7.64 (s, 1H, CH=), 7.61 (s, 1H, benzoimidazole) 7.56 (d, J = 8.9 Hz, 1H, Ar), 7.34 (s, 2H, benzoimidazole), 7.12 (d, J = 8.8 Hz, 1H, Ar). Anal. Calculated for C18H11N3O4S2 %: C, 54.40; H, 2.79; N, 10.57. Found %: C, 54.02; H, 2.84; N, 10.66.
Primary anticancer assay was performed at approximatelysixty human tumor cell lines panel derived from nine neoplasticdiseases, in accordance with the protocol of the Drug Evaluation Branch, National Cancer Institute, Bethesda (
Using the absorbance measurements [time zero, (Tz); control growth in the absence of drug, (C); and test growth in the presence of drug at the mentioned concentration (Ti)], the percentage growth inhibition was as:
[(Ti- Tz) / (C - Tz)] × 100 whenTi³Tz,
[(Ti - Tz) / Tz] × 100 whenTi<Tz.
spectrophotometrically versus controls not treated with the test agents.
Continuing our works (
We investigated the reaction of 1H-benzoimidazole-2-carbaldehyde with 4-oxo-2-thioxothiazolidin-3-ylcarboxilic acids. We found that the optimal condition for the condensation is boiling acetic acid in presence of sodium acetate as a catalyst. As the result a series of novel derivatives [5-(1H-benzoimidazol-2-ylmethylene)-4-oxo-2-thioxo-thiazolidine-3-ylcarboxilc acid 8-10 were prepared (Scheme
The structure of compounds 8-10 was confirmed by 1H NMR spectroscopy. In 1H NMR spectra, signals for the protons of all the structural units were observed in their characteristic ranges. The chemical shift for the methylidene group is insignificantly displaced in a weak magnetic field, δ = 7,60–7,68 ppm and clearly indicated that only Z-isomers were obtained. NH proton of benzoimidazole ring shows the singlet at 13,08–13,20 ppm. Due to steric hindrances, the rotation around the N-C bond in the position 3 in compound 8b is difficult and the methyl groups are not equivalent. The protons of methyl groups appear as two doublets at 0.76 and 1.20 ppm. Similar effects are observed in the case of compound 8c.
The synthesized compounds were selected by the National Cancer Institute (NCI) Developmental Therapeutic Program (www.dtp.nci.nih.gov) for the in vitro cell line screening to investigate their anticancer activity. Anticancer assays were performed according to the NCI protocol, which is described elsewhere (
The tested compounds displayed a weak to medium anticancer activity. The most sensitive cell lines turned out to be SNB-75 of CNS Cancer (GP = 74.84–85.73%) and UO-31, Renal cancer (GP = 71.53–82.16%) and to compound 10a K-562 Leukemia cell lines (GP = 57.14). It should also be noticed that all compounds stimulate the growing of CCRF-CEM and SR Leukemia cell lines.
Cytotoxic activity of the tested compounds in the concentration 10−5 M against 60 cancer cell lines.
Test compounds | Mitotic activity 60 cancer cell lines GP % | Most sensitive cell line (cancer line/type) GP, % | |
---|---|---|---|
Average growth, % | Range of growth, % | ||
8a | 98.93 | 74.37–143.90 | SNB-75 (CNS Cancer) 83.89 |
MALME-3M (Melanoma) 81.63 | |||
UO-31 (Renal Cancer) 74.37 | |||
8b | 100.30 | 76.42–122.20 | SNB-75 (CNS Cancer) 83.70 |
UO-31 (Renal Cancer) 76.42 | |||
8c | 100.49 | 78.88–127.16 | SNB-75 (CNS Cancer) 78.88 |
UO-31 (Renal Cancer) 80.50 | |||
8d | 101.36 | 73.79–154.33 | SNB-75 (CNS Cancer) 85.73 |
UO-31 (Renal Cancer) 73.79 | |||
8e | 101.23 | 81.40–136.54 | SNB-75 (CNS Cancer) 81.40 |
UO-31 (Renal Cancer) 82.16 | |||
8f | 101.06 | 71.53–127.99 | SNB-75 (CNS Cancer) 78.08 |
CAKI-1 (Renal Cancer) 83.37 | |||
UO-31 (Renal Cancer) 71.53 | |||
9 | 98.79 | 73.24–123.19 | SNB-75 (CNS Cancer) 75.43 |
UO-31 (CNS Cancer) 73.24 | |||
10a | 99.38 | 57.14–111.51 | K-562 (Leukemia) 57.14 |
SNB-75 (CNS Cancer) 74.84 | |||
UO-31 (Renal Cancer) 76.84 | |||
10b | 101.36 | 73.79–154.33 | SNB-75 (CNS Cancer) 85.73 |
UO-31 (Renal Cancer) 73.79 |
In our work, we presented an efficient synthesis and anticancer activity evaluation of some 5-(1H-benzoimidazol-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-ylcarboxilic acids. First, anticancer activity was detected among the compounds tested. Further optimization of the structure to improve their activities is currently in progress.